Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Rhythm Pharmaceuticals (NASDAQ:RYTM) Inc stock reached an all-time high of 95.05 USD, marking a significant milestone for the biotechnology company. With a market capitalization of $6.29 billion and impressive gross profit margins of 89%, the company has demonstrated strong financial metrics. Over the past year, the company’s stock has delivered a remarkable 112% return, though InvestingPro analysis indicates the stock may be slightly overvalued at current levels. This surge reflects growing investor confidence and interest in Rhythm Pharmaceuticals’ potential within the biotech sector, with revenue growth of 53.55% in the last twelve months. The stock’s performance underscores the company’s progress and market optimism about its future prospects, as it continues to develop innovative treatments targeting rare genetic disorders of obesity. With a beta of 2.39 indicating higher volatility, investors can access comprehensive technical analysis and 14 additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Rhythm Pharmaceuticals reported its second-quarter 2025 earnings, revealing a wider-than-expected loss per share. The company’s earnings per share came in at -$0.75, missing analyst forecasts of -$0.67. Despite the earnings miss, Rhythm Pharmaceuticals’ revenue reached $48.5 million, surpassing the forecast of $43.75 million and representing a 29% increase quarter-over-quarter. This strong revenue performance led H.C. Wainwright to raise its price target for the company from $80 to $100, maintaining a Buy rating. Similarly, TD Cowen increased its price target from $85 to $110, citing the robust revenue growth that exceeded expectations. Citizens JMP also raised its price target to $135 from $130, maintaining a Market Outperform rating. The firm highlighted the continued growth in demand for Imcivree and noted the company’s progress in regulatory applications for setmelanotide for hypothalamic obesity in the U.S. and EU. These developments reflect the positive momentum surrounding Rhythm Pharmaceuticals’ recent performance and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.